Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b

Hepatology Research

Volumn 39, Issue 6, 2009, Pages 539-545

  Tseng, Kuo Chih ^a,b   Chen, Li Hsuan ^c   Chen, Chi Yi ^d   Chang, Ting Tsung ^e   Chou, An Liang ^a   Wu, I Chin ^e   Cheng, Pin Nan ^e  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Anemia; Erythropoietin; Hepatitis C virus; Interferon alfa; Ribavirin

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; BLOOD ANALYSIS; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 66449084721     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00489.x     Document Type: Article

References (28)

1. National Institute of Health (NIH). NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
2. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (Suppl 1): S237 -44.
3. Russo MW, Fried MW. Side effect of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-9.
4. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-50.
5. De Franceschi L, Fattovich G, Turrini F etal. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
6. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997; 26: 473-7.
7. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-a. Gastroenterology 2002; 123: 141-51.
8. Ernstoff MS, Kirkwood JM. Changes in the bone marrow of cancer patients treated with recombinant inferferon alpha-2. Am J Med 1984; 76: 593-6.
9. Balan V, Schwartz D, Wu GY et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ ribavirin. Am J Gastroenterol 2005; 100: 299-307.
10. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19 (Suppl 1): 67-75.
11. McHutchison JG, Manns MP, Brown RS Jr, Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102: 880-9.
12. Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-a. Am J Gastroenterol 2001; 96: 2802-4.
13. Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002; 35: 1281-2.
14. Dieterich DT, Wasserman R, Bräu N et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 2491-9.
15. Afdhal NH, Dieterich DT, Pockros PJ etal. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302-11.
16. Pockros PJ, Shiffman ML, Schiff ER et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40: 1450-8.
17. Pujade-Lauraine E, Topham C. Once-weekly treatment of anemia in patients with cancer: A comparative review of epoetins. Oncology 2005; 68: 122-9.
18. Durante Mangoni E, Marrone A, Saviano D, Del Vecchio C, Utili R, Ruggiero G. Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anemia. Antivir Ther 2003; 8: 57-63.
19. French METAVIR Cooperative Study Group (The). Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
20. Schering-Plough Corporation. PEG-Intron [package insert]. Kenilworth, NJ: Schering-Plough Corporation, 2003.
21. McHutchison JG, Manns M, Patel K etal. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
22. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
23. Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 371-9.
24. Younossi ZM, Nader FH, Bai C et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat 2008; 15: 370-8.
25. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888-95.
26. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82.
27. Lebray P, Nalpas B, Vallet-Pichard A et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antivir Ther 2005; 10: 769-76.
28. Oberhoff C. Speed of haemoglobin response in patients with cancer: A review of the erythropoietic proteins. Support Care Cancer 2007; 15: 603-11.